Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In China
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: Aromasin (exemestane)
Sponsor: Pfizer